Fluxome cash crisis caused by “gross mismanagement”

By Shane STARLING contact

- Last updated on GMT

Fluxome bankruptcy threat caused by “gross mismanagement”
Management at embattled resveratrol supplier Fluxome has come in for severe criticism as the company hovers on the verge of financial collapse unless a fresh investor can be found in the coming weeks.

An observer close to a situation that saw 21 Fluxome employees at its Danish premise dismissed last Thursday without prior notice and pay for the month of September, said rash spending on new hires and premise expansion drove the company into the ground.

“While the company was struggling financially, they go and hire a new CEO, sales director [based in the US] and open offices in Maryland in the US – it’s just gross mismanagement,” ​the observer said.

“They knew they needed a new investor so it was just a bluff to get interest in the company.”

But chairman Jarne Elleholm said the company had filed for “formal reconstruction” ​in Danish courts last week almost exclusively as a result of the last-minute pull-out of an investor that would have driven the company’s ambitious omega-3 yeast extraction programme forward.

That programme was run by Dr Birgitte Wittschieben out of the now closed premise in Denmark. Its US operation continues to function.

“There was a party ready to invest but everything changed overnight when they pulled out at the last minute,” ​said Elleholm.

“Formal reconstruction”

He said the new “formal reconstruction” ​procedure in Danish law offered a better means to take the company forward than filing for bankruptcy. That motion is set to be heard in Danish courts on October 22.

He said he did not know if the 21 staff would eventually be paid – “it depends on the court”.

The “formal reconstruction” ​law gives companies more time to deal with financial problems, and de-prioritises the payment of salaries, unlike bankruptcy laws.

Board member Isabelle de Cremoux, from Paris-based investment firm, Seventure, said the firm was involved in restructuring plans.

“We were in late stage discussions with another investor with whom we, the current venture capital shareholders, were considering refinancing.”

“But he suddenly dropped out, hence the situation. If we find a new co-investor, we are likely to participate to the refinancing.”

Elleholm said 3-4 investors were in the picture for such refinancing.

Related news

Show more

Related products

show more

NEW First Full-Spectrum Vitamin K2 from MenaQ7®

NEW First Full-Spectrum Vitamin K2 from MenaQ7®

NattoPharma USA, Inc. | 19-Feb-2018 | Data Sheet

Natural product consumers are drawn to comprehensive nutritional sources, but attaining our daily Vitamin K2 requirement from a Western diet is not a viable...

Setting Specifications – Don’t Forget To Do This!

Setting Specifications – Don’t Forget To Do This!

Gemini Pharmaceuticals | 12-Feb-2018 | Technical / White Paper

While the regulations require Brand Owners to establish specifications for all raw materials and for the finished product, based on the number of FDA Warning...

SelenoForce®: Micro-Nutrient with Macro-Potential

SelenoForce®: Micro-Nutrient with Macro-Potential

Sabinsa Corporation | 29-Jan-2018 | Data Sheet

A safe and bioavailable source of supplemental selenium, this selenium-enriched garlic product is manufactured by a patented soil-less culture technique,...

A new generation of ginger

A new generation of ginger

Naturex | 12-Dec-2017 | Data Sheet

Ginger is poised to become the next botanical superstar and presents particular promise for the digestive health category. Despite its growing popularity,...

Related suppliers

Follow us


View more